Original data (with adjusted standard errors for multi-arm studies):

              treat1      treat2      TE   seTE seTE.adj.f seTE.adj.r narms multiarm
10           placebo    zolpidem  0.0379 0.1077     0.1077     0.1811     2         
12       eszopiclone     placebo -0.5283 0.4674     0.4674     0.4895     2         
45           placebo  suvorexant  0.4377 0.0964     0.0964     0.1746     2         
46           placebo  suvorexant  0.4089 0.1068     0.1068     0.1805     2         
47           placebo    zolpidem  0.8141 0.4546     0.4546     0.4774     2         
51          BZD-long     placebo  0.0453 0.2458     0.2843     0.3356     3        *
51         BZD-short     placebo  0.0781 0.2829     0.3981     0.4288     3        *
51          BZD-long   BZD-short -0.0328 0.2458     0.2843     0.3355     3        *
52          BZD-long   zopiclone  0.0792 0.6327     0.6327     0.6492     2         
54  BZD-intermediate    BZD-long  0.1958 0.5787     0.5787     0.5968     2         
55          BZD-long   BZD-short  0.6459 0.5922     0.5922     0.6098     2         
56  BZD-intermediate   BZD-short  0.6720 0.5934     0.5934     0.6110     2         
60           doxepin     placebo -0.4267 0.1584     0.1584     0.2151     2         
61           doxepin     placebo -0.4135 0.1417     0.1417     0.2031     2         
70         melatonin     placebo  0.2601 0.3176     0.3176     0.3493     2         
71          BZD-long   BZD-short -0.3008 0.5806     0.5806     0.5986     2         
77       eszopiclone     placebo -0.2518 0.1259     0.1259     0.1924     2         
80           placebo    zolpidem  1.3541 0.6401     0.6401     0.6564     2         
81           placebo    zolpidem  1.0571 0.6164     0.6164     0.6333     2         
83  BZD-intermediate     placebo -0.6926 0.3586     0.3586     0.3870     2         
99      daridorexant    zolpidem -0.2253 0.1446     0.1587     0.2386     3        *
99           placebo    zolpidem  0.0120 0.1826     0.3139     0.3233     3        *
99      daridorexant     placebo -0.2373 0.1447     0.1587     0.2387     3        *
112          placebo    zolpidem  0.4571 0.2125     0.2125     0.2576     2         
114          placebo    zolpidem  0.7140 0.1463     0.1463     0.2064     2         
122          placebo   zopiclone  0.5786 0.4015     0.4015     0.4271     2         
134          placebo    zaleplon  0.1309 0.2044     0.2044     0.2509     2         
137          placebo    zolpidem  0.3869 0.1436     0.1436     0.2045     2         
140        BZD-short    zolpidem -0.5517 0.2535     0.3147     0.3617     3        *
140          placebo    zolpidem  0.2145 0.2413     0.2865     0.3371     3        *
140        BZD-short     placebo -0.7662 0.2547     0.3179     0.3644     3        *
144      eszopiclone     placebo -0.3427 0.1228     0.1228     0.1904     2         
145          placebo   ramelteon -0.0980 0.1218     0.1218     0.1898     2         
153      lemborexant    zolpidem -0.2360 0.0771     0.0866     0.1969     3        *
153          placebo    zolpidem  0.3840 0.0953     0.1386     0.2200     3        *
153      lemborexant     placebo -0.6199 0.0844     0.0985     0.2047     3        *
154      lemborexant     placebo -0.3609 0.1845     0.1845     0.2350     2         
158          placebo seltorexant  0.3334 0.1401     0.1567     0.2375     3        *
158          placebo    zolpidem  0.2718 0.1712     0.2722     0.3032     3        *
158      seltorexant    zolpidem -0.0617 0.1388     0.1547     0.2358     3        *
159     daridorexant     placebo -0.5900 0.0709     0.0709     0.1619     2         
160     daridorexant     placebo -0.3153 0.0810     0.0810     0.1666     2         

Number of treatment arms (by study):
    narms
10      2
12      2
45      2
46      2
47      2
51      3
52      2
54      2
55      2
56      2
60      2
61      2
70      2
71      2
77      2
80      2
81      2
83      2
99      3
112     2
114     2
122     2
134     2
137     2
140     3
144     2
145     2
153     3
154     2
158     3
159     2
160     2

Results (fixed effects model):

              treat1      treat2     SMD             95%-CI    Q leverage
10           placebo    zolpidem  0.3153 [ 0.2210;  0.4097] 6.63     0.20
12       eszopiclone     placebo -0.3062 [-0.4755; -0.1369] 0.23     0.03
45           placebo  suvorexant  0.4248 [ 0.2845;  0.5651] 0.02     0.55
46           placebo  suvorexant  0.4248 [ 0.2845;  0.5651] 0.02     0.45
47           placebo    zolpidem  0.3153 [ 0.2210;  0.4097] 1.20     0.01
51          BZD-long     placebo -0.3178 [-0.6945;  0.0590] 1.63        .
51         BZD-short     placebo -0.5323 [-0.8576; -0.2069] 2.35        .
51          BZD-long   BZD-short  0.2145 [-0.1501;  0.5791] 0.76        .
52          BZD-long   zopiclone  0.2087 [-0.5080;  0.9253] 0.04     0.33
54  BZD-intermediate    BZD-long -0.0758 [-0.6714;  0.5199] 0.22     0.28
55          BZD-long   BZD-short  0.2145 [-0.1501;  0.5791] 0.53     0.10
56  BZD-intermediate   BZD-short  0.1387 [-0.4406;  0.7180] 0.81     0.25
60           doxepin     placebo -0.4194 [-0.6263; -0.2124] 0.00     0.44
61           doxepin     placebo -0.4194 [-0.6263; -0.2124] 0.00     0.56
70         melatonin     placebo  0.2601 [-0.3623;  0.8825] 0.00     1.00
71          BZD-long   BZD-short  0.2145 [-0.1501;  0.5791] 0.79     0.10
77       eszopiclone     placebo -0.3062 [-0.4755; -0.1369] 0.19     0.47
80           placebo    zolpidem  0.3153 [ 0.2210;  0.4097] 2.63     0.01
81           placebo    zolpidem  0.3153 [ 0.2210;  0.4097] 1.45     0.01
83  BZD-intermediate     placebo -0.3935 [-0.9405;  0.1534] 0.70     0.61
99      daridorexant    zolpidem -0.1405 [-0.2679; -0.0130] 0.29        .
99           placebo    zolpidem  0.3153 [ 0.2210;  0.4097] 0.93        .
99      daridorexant     placebo -0.4558 [-0.5506; -0.3610] 1.89        .
112          placebo    zolpidem  0.3153 [ 0.2210;  0.4097] 0.45     0.05
114          placebo    zolpidem  0.3153 [ 0.2210;  0.4097] 7.43     0.11
122          placebo   zopiclone  0.5264 [-0.1467;  1.1996] 0.02     0.73
134          placebo    zaleplon  0.1309 [-0.2697;  0.5315] 0.00     1.00
137          placebo    zolpidem  0.3153 [ 0.2210;  0.4097] 0.25     0.11
140        BZD-short    zolpidem -0.2169 [-0.5483;  0.1145] 1.13        .
140          placebo    zolpidem  0.3153 [ 0.2210;  0.4097] 0.12        .
140        BZD-short     placebo -0.5323 [-0.8576; -0.2069] 0.54        .
144      eszopiclone     placebo -0.3062 [-0.4755; -0.1369] 0.09     0.49
145          placebo   ramelteon -0.0980 [-0.3368;  0.1408] 0.00     1.00
153      lemborexant    zolpidem -0.2415 [-0.3706; -0.1125] 0.00        .
153          placebo    zolpidem  0.3153 [ 0.2210;  0.4097] 0.25        .
153      lemborexant     placebo -0.5569 [-0.6861; -0.4276] 0.41        .
154      lemborexant     placebo -0.5569 [-0.6861; -0.4276] 1.13     0.13
158          placebo seltorexant  0.3555 [ 0.1345;  0.5765] 0.02        .
158          placebo    zolpidem  0.3153 [ 0.2210;  0.4097] 0.03        .
158      seltorexant    zolpidem -0.0402 [-0.2609;  0.1805] 0.02        .
159     daridorexant     placebo -0.4558 [-0.5506; -0.3610] 3.58     0.47
160     daridorexant     placebo -0.4558 [-0.5506; -0.3610] 3.01     0.36

Results (random effects model):

              treat1      treat2     SMD             95%-CI
10           placebo    zolpidem  0.3299 [ 0.1904;  0.4694]
12       eszopiclone     placebo -0.3141 [-0.5698; -0.0584]
45           placebo  suvorexant  0.4238 [ 0.1778;  0.6698]
46           placebo  suvorexant  0.4238 [ 0.1778;  0.6698]
47           placebo    zolpidem  0.3299 [ 0.1904;  0.4694]
51          BZD-long     placebo -0.3310 [-0.7591;  0.0972]
51         BZD-short     placebo -0.5382 [-0.9055; -0.1709]
51          BZD-long   BZD-short  0.2072 [-0.2037;  0.6181]
52          BZD-long   zopiclone  0.1967 [-0.5637;  0.9572]
54  BZD-intermediate    BZD-long -0.0509 [-0.6877;  0.5859]
55          BZD-long   BZD-short  0.2072 [-0.2037;  0.6181]
56  BZD-intermediate   BZD-short  0.1563 [-0.4607;  0.7733]
60           doxepin     placebo -0.4197 [-0.7092; -0.1303]
61           doxepin     placebo -0.4197 [-0.7092; -0.1303]
70         melatonin     placebo  0.2601 [-0.4245;  0.9448]
71          BZD-long   BZD-short  0.2072 [-0.2037;  0.6181]
77       eszopiclone     placebo -0.3141 [-0.5698; -0.0584]
80           placebo    zolpidem  0.3299 [ 0.1904;  0.4694]
81           placebo    zolpidem  0.3299 [ 0.1904;  0.4694]
83  BZD-intermediate     placebo -0.3819 [-0.9648;  0.2010]
99      daridorexant    zolpidem -0.1073 [-0.3284;  0.1137]
99           placebo    zolpidem  0.3299 [ 0.1904;  0.4694]
99      daridorexant     placebo -0.4372 [-0.6260; -0.2484]
112          placebo    zolpidem  0.3299 [ 0.1904;  0.4694]
114          placebo    zolpidem  0.3299 [ 0.1904;  0.4694]
122          placebo   zopiclone  0.5277 [-0.1834;  1.2389]
134          placebo    zaleplon  0.1309 [-0.3609;  0.6227]
137          placebo    zolpidem  0.3299 [ 0.1904;  0.4694]
140        BZD-short    zolpidem -0.2083 [-0.5878;  0.1712]
140          placebo    zolpidem  0.3299 [ 0.1904;  0.4694]
140        BZD-short     placebo -0.5382 [-0.9055; -0.1709]
144      eszopiclone     placebo -0.3141 [-0.5698; -0.0584]
145          placebo   ramelteon -0.0980 [-0.4701;  0.2740]
153      lemborexant    zolpidem -0.2002 [-0.4536;  0.0531]
153          placebo    zolpidem  0.3299 [ 0.1904;  0.4694]
153      lemborexant     placebo -0.5301 [-0.7741; -0.2862]
154      lemborexant     placebo -0.5301 [-0.7741; -0.2862]
158          placebo seltorexant  0.3627 [ 0.0273;  0.6981]
158          placebo    zolpidem  0.3299 [ 0.1904;  0.4694]
158      seltorexant    zolpidem -0.0328 [-0.3680;  0.3024]
159     daridorexant     placebo -0.4372 [-0.6260; -0.2484]
160     daridorexant     placebo -0.4372 [-0.6260; -0.2484]

Number of studies: k = 32
Number of pairwise comparisons: m = 42
Number of observations: o = 6779
Number of treatments: n = 15
Number of designs: d = 20

Fixed effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                     SMD             95%-CI     z  p-value
BZD-intermediate -0.3935 [-0.9405;  0.1534] -1.41   0.1584
BZD-long         -0.3178 [-0.6945;  0.0590] -1.65   0.0983
BZD-short        -0.5323 [-0.8576; -0.2069] -3.21   0.0013
daridorexant     -0.4558 [-0.5506; -0.3610] -9.42 < 0.0001
doxepin          -0.4194 [-0.6263; -0.2124] -3.97 < 0.0001
eszopiclone      -0.3062 [-0.4755; -0.1369] -3.55   0.0004
lemborexant      -0.5569 [-0.6861; -0.4276] -8.45 < 0.0001
melatonin         0.2601 [-0.3623;  0.8825]  0.82   0.4127
placebo                .                  .     .        .
ramelteon         0.0980 [-0.1408;  0.3368]  0.80   0.4211
seltorexant      -0.3555 [-0.5765; -0.1345] -3.15   0.0016
suvorexant       -0.4248 [-0.5651; -0.2845] -5.94 < 0.0001
zaleplon         -0.1309 [-0.5315;  0.2697] -0.64   0.5219
zolpidem         -0.3153 [-0.4097; -0.2210] -6.55 < 0.0001
zopiclone        -0.5264 [-1.1996;  0.1467] -1.53   0.1253

Random effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                     SMD             95%-CI     z  p-value             95%-PI
BZD-intermediate -0.3819 [-0.9648;  0.2010] -1.28   0.1991 [-1.0685;  0.3047]
BZD-long         -0.3310 [-0.7591;  0.0972] -1.52   0.1297 [-0.8753;  0.2134]
BZD-short        -0.5382 [-0.9055; -0.1709] -2.87   0.0041 [-1.0303; -0.0461]
daridorexant     -0.4372 [-0.6260; -0.2484] -4.54 < 0.0001 [-0.7992; -0.0753]
doxepin          -0.4197 [-0.7092; -0.1303] -2.84   0.0045 [-0.8497;  0.0103]
eszopiclone      -0.3141 [-0.5698; -0.0584] -2.41   0.0160 [-0.7194;  0.0912]
lemborexant      -0.5301 [-0.7741; -0.2862] -4.26 < 0.0001 [-0.9273; -0.1330]
melatonin         0.2601 [-0.4245;  0.9448]  0.74   0.4565 [-0.5247;  1.0449]
placebo                .                  .     .        .                  .
ramelteon         0.0980 [-0.2740;  0.4701]  0.52   0.6055 [-0.3980;  0.5941]
seltorexant      -0.3627 [-0.6981; -0.0273] -2.12   0.0341 [-0.8286;  0.1032]
suvorexant       -0.4238 [-0.6698; -0.1778] -3.38   0.0007 [-0.8223; -0.0252]
zaleplon         -0.1309 [-0.6227;  0.3609] -0.52   0.6019 [-0.7325;  0.4707]
zolpidem         -0.3299 [-0.4694; -0.1904] -4.63 < 0.0001 [-0.6659;  0.0061]
zopiclone        -0.5277 [-1.2389;  0.1834] -1.45   0.1458 [-1.3385;  0.2830]

Quantifying heterogeneity / inconsistency:
tau^2 = 0.0212; tau = 0.1455; I^2 = 44.9% [10.9%; 66.0%]

Tests of heterogeneity (within designs) and inconsistency (between designs):
                    Q d.f. p-value
Total           41.77   23  0.0096
Within designs  28.08   12  0.0054
Between designs 13.69   11  0.2504
[1] "A total of 15 treatments are included in the network."
[1] "A total of 32 studies are included in this analysis."
[1] "A total of 6779 participants are included in this analysis."
[1] "The following studies were included in this analysis: 10 12 45 46 47 51 52 54 55 56 60 61 70 71 77 80 81 83 99 112 114 122 134 137 140 144 145 153 154 158 159 160"
[1] "Estimated heterogeneity tau-squared0.02"
[1] "Global test for inconsistency, p-value 0.25036 (Q=14, d.o.f. 11)"
[1] "File created on 2022-01-31"
